Future Science Group
supplementary material.docx (550.5 kB)

The societal impact of early intensified treatment in patients with type 2 diabetes mellitus: Supplementary material

Download (550.5 kB)
posted on 2022-09-28, 16:11 authored by Foteini Tsotra, Mathias Kappel, Platon Peristeris, Giovanni Bader, Eva Levi, Nicola Lister, Ankur Malhotra, Dennis A Ostwald

Aim: The current study estimates the societal impact of early intensified treatment compared with initial

monotherapy with subsequent treatment intensification in newly diagnosed adults with type 2 diabetes

mellitus in Mexico. Methods: An individual patient-level simulation and a static cohort model were

employed to simulate the treatment pathway and the probability of experiencing complications of

diabetes. The avoided number of events was translated into avoided productivity losses, which were

monetized using wages. Results: Patients on early intensified treatment experienced approximately

13,000 fewer complication events over 10 years. This was translated into a societal impact of $54 million

(USD). Conclusion: Early treatment intensification is likely to be of particular benefit to health outcomes

and productivity losses.


This work was funded by Novartis Pharma AG. F Tsotra, P Peristeris, E Levi and M Kappel are employees of WifOR institute, an independent economic research institute in Darmstadt, DA Ostwald is the CEO of WifOR institute. G Bader, A Malhotra and N Lister are employees of Novartis.